Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13807

Full metadata record

DC Field	Value	Language
dc.contributor.author	Chowdhury, Rajdeep	-
dc.contributor.author	Roy, Aniruddha	-
dc.date.accessioned	2024-01-11T06:31:28Z	-
dc.date.available	2024-01-11T06:31:28Z	-
dc.date.issued	2020-07	-
dc.identifier.uri	https://link.springer.com/article/10.1007/s43440-020-00122-1	-
dc.identifier.uri	http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13807	-
dc.description.abstract	Recent studies have demonstrated that autophagy plays a critical role in reducing the drug sensitivity of docetaxel (DTX) therapy. Disulfiram (DSF) has exhibited potent autophagy inducing activity in multiple studies. We hypothesized that DSF co-treatment could sensitize breast cancer cells to DTX therapy via autophagy modulation.	en_US
dc.language.iso	en	en_US
dc.publisher	Springer	en_US
dc.subject	Pharmacy	en_US
dc.subject	Disulfiram	en_US
dc.subject	Breast cancer	en_US
dc.subject	Autophagy	en_US
dc.title	Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy	en_US
dc.type	Article	en_US
Appears in Collections:	Department of Pharmacy

Files in This Item:

There are no files associated with this item.